The poor experience of the HTA Review was predictable and predicted. While, in many ways, it might be too late to correct, there are valuable lessons that can guide advocacy over the years ahead. The primary lesson is prioritising caution over misplaced and frankly naive enthusiasm for controlled processes run by the all-powerful single-payer.
The process looked like a teddy bear, but a closer look has revealed a hidden risk
March 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech
